Table 3

Serum levels of resistin, S100A12 and soluble receptor for advanced glycation end products (sRAGE) in Kawasaki disease (KD) with or without coronary artery lesions (CALs)

Characteristic

KD with CALs

(n = 9)

KD without CALs

(n = 31)

P


Boys/girls, number

4/5

18/13

0.000

Age, months

27.1 (20.7)

22.1 (15.6)

0.001

Resistin, 102 ng/ml

Acute stage

0.46 (0.24)

0.36 (0.26)

0.268

Afebrile stage

0.31 (0.20)

0.22 (0.22) *

0.266

Subacute stage

0.15 (0.08)**

0.13 (0.08) **

0.663

S100A12, 102 ng/ml

Acute stage

5.09 (2.78)

5.40 (3.42)

0.804

Afebrile stage

4.22 (3.29)

4.02 (3.63)

0.883

Subacute stage

2.52 (3.16)

2.65 (2.53)**

0.899

sRAGE, 102 pg/ml

Acute stage

2.97(1.99)

3.01 (1.92)

0.959

Afebrile stage

5.93 (3.59)*

5.70 (2.64)**

0.833

Subacute stage

7.06 (3.88)*

6.77 (2.86)**

0.802


Results are mean (SD) unless stated otherwise. *P < 0.05, **P < 0.01 compared with acute stage; P < 0.05 compared with group afebrile stage.

Qi et al. Arthritis Research & Therapy 2012 14:R251   doi:10.1186/ar4094

Open Data